Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Source data Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material
Gut hormone polyagonists for the treatment of type 2 diabetes
This highlights why a personalized approach is so vital
Walkowski, B., Kleibert, M., Majka, M
At Blue Horizon, we are here to provide the data that helps you and your doctor find the best path forward for your unique body
The National Institute of Diabetes and Digestive and Kidney Diseases, the Endocrine Society, and major obesity medicine organizations recognize GLP-1 receptor agonists as evidence-based interventions for obesity management in appropriately selected adult patients
US$ 21.73
US$ 29.75
US$ 27.76
US$ 21.00
US$ 22.38
US$ 20.49
US$ 25.35
US$ 27.14
US$ 26.26
US$ 21.88
